Peritonitis is a life-threatening event that is often accompanied by bacteremia and sepsis. Primary peritonitis has no apparent source, whereas secondary peritonitis is caused by spillage from an intraabdominal viscus. The etiologic organisms and the clinical presentations of these two processes are different.
Primary (Spontaneous) Bacterial Peritonitis
- Epidemiology: Primary bacterial peritonitis (PBP) is most common among pts with cirrhosis (usually due to alcoholism) and preexisting ascites, but ≤10% of these pts develop PBP. PBP is also described in other settings (e.g., malignancy, hepatitis).
- Pathogenesis: PBP is due to hematogenous spread of organisms to ascitic fluid in pts in whom a diseased liver and altered portal circulation compromise the liver's filtration function.
- Microbiology: Enteric gram-negative bacilli such as Escherichia coli or gram-positive organisms such as streptococci, enterococci, and pneumococci are the most common etiologic agents.
- A single organism is typically isolated.
- If a polymicrobial infection including anaerobes is identified, the diagnosis of PBP should be reconsidered and a source of secondary peritonitis sought.
- Clinical manifestations: Although some pts experience acute-onset abdominal pain or signs of peritoneal irritation, other pts have only nonspecific and nonlocalizing manifestations (e.g., malaise, fatigue, encephalopathy). Fever is common (∼80% of pts).
- Diagnosis: PBP is diagnosed if peritoneal fluid is sampled and contains >250 PMNs/µL.
- Culture yield is improved if a 10-mL volume of peritoneal fluid is placed directly into blood culture bottles.
- Blood cultures should be performed because bacteremia is common.
- Prevention: Up to 70% of pts have a recurrence of PBP within 1 year. Prophylaxis with fluoroquinolones (e.g., ciprofloxacin, 500 mg weekly) or trimethoprim-sulfamethoxazole (TMP-SMX; one double-strength tablet daily) reduces this rate to 20% but increases the risk of serious staphylococcal infections over time.
TREATMENT |
Primary (Spontaneous) Bacterial Peritonitis
A third-generation cephalosporin (e.g., ceftriaxone, 2 g q24h IV; or cefotaxime, 2 g q8h IV) or piperacillin/tazobactam (3.375 g qid IV) constitutes appropriate empirical treatment. - The regimen should be narrowed after the etiology is identified.
- Treatment should continue for at least 5 days, but longer courses (up to 2 weeks) may be needed for pts with coexisting bacteremia or for those whose improvement is slow.
- Albumin (1.5 g/kg of body weight within 6 h of detection and 1.0 g/kg on day 3) improves survival rates among pts with serum creatinine levels ≥1 mg/dL, BUN levels ≥30 mg/dL, or total bilirubin levels ≥4 mg/dL.
|
Secondary Peritonitis
- Pathogenesis: Secondary peritonitis develops when bacteria contaminate the peritoneum as a result of spillage from an intraabdominal viscus.
- Microbiology: Infection almost always involves a mixed flora in which gram-negative bacilli and anaerobes predominate, especially when the contaminating source is colonic. The specific organisms depend on the flora present at the site of the initial process.
- Clinical manifestations: Initial symptoms may be localized or vague and depend on the primary organ involved. Once infection has spread to the peritoneal cavity, pain increases; pts lie motionless, often with knees drawn up to avoid stretching the nerve fibers of the peritoneal cavity. Coughing or sneezing causes severe, sharp pain. There is marked voluntary and involuntary guarding of anterior abdominal musculature, tenderness (often with rebound), and fever.
- Diagnosis: Although recovery of organisms from peritoneal fluid is easier in secondary than in primary peritonitis, radiographic studies to find the source of peritoneal contamination or immediate surgical intervention should usually be part of the initial diagnostic evaluation. Abdominal taps are done only to exclude hemoperitoneum in trauma cases.
TREATMENT |
Secondary Peritonitis
- Antibiotics aimed at the inciting microbes-e.g., penicillin/β-lactamase inhibitor combinations or a combination of a fluoroquinolone or a third-generation cephalosporin plus metronidazole-should be administered early.
- Critically ill pts in the ICU and/or those with health care-associated infections should be treated for the possibility of resistant gram-negative organisms, including Pseudomonas aeruginosa, with a carbapenem-e.g., imipenem (500 mg q6h IV), meropenem (1 g q8h IV), higher-dose piperacillin/tazobactam (4.5 g q6h IV), or drug combinations such as metronidazole plus either cefepime (2 g IV q8h) or ceftazidime (2 g IV q8h). These regimens can be altered on the basis of the pt's history of resistant organisms and/or concern about enterococcal or fungal involvement.
- Surgical intervention is often needed.
|
Peritonitis In Pts Undergoing Capd
- Pathogenesis: In a phenomenon similar to that seen in intravascular device-related infections, organisms migrate along the catheter-a foreign body that serves as an entry point.
- Microbiology: CAPD-associated peritonitis usually involves skin organisms, with Staphylococcus spp. such as coagulase-negative staphylococci and Staphylococcus aureus accounting for ∼45% of cases; gram-negative bacilli and fungi (e.g., Candida) are occasionally identified. A polymicrobial infection should prompt evaluation for secondary peritonitis.
- Clinical manifestations: CAPD-associated peritonitis presents similarly to secondary peritonitis, in that diffuse pain and peritoneal signs are common.
- Diagnosis: Several hundred milliliters of removed dialysis fluid should be centrifuged and sent for culture.
- Use of blood culture bottles improves the diagnostic yield.
- The dialysate is usually cloudy and contains >100 WBCs/µL, with >50% neutrophils; the percentage of neutrophils is more important than the absolute WBC count.
TREATMENT |
Peritonitis in Pts Undergoing CAPD
- Empirical therapy should be directed against staphylococcal species and gram-negative bacilli (e.g., cefazolin plus a fluoroquinolone or a third-generation cephalosporin such as ceftazidime). Vancomycin should be used instead of cefazolin if methicillin resistance is prevalent, if the pt has an overt exit-site infection, or if the pt appears toxic.
- Antibiotics are given by the IP route either continuously (e.g., with each exchange) or intermittently (e.g., once daily, with the dose allowed to remain in the peritoneal cavity for 6 h). Severely ill pts should be given the same regimen by the IV route.
- Catheter removal should be considered in fungal infection, for pts with exit-site or tunnel infection, or if the pt's condition does not improve within 48-96 h.
- Uncomplicated CAPD-associated peritonitis should be treated for 14 days; up to 21 days may be necessary in pts with exit-site or tunnel infection.
|